key: cord-0877086-q7e5fbv3 authors: Jorge-Aarón, Rangel-Méndez; Rosa-Ester, Moo-Puc title: N-acetylcysteine as a potential treatment for novel coronavirus disease 2019 date: 2020-07-14 journal: Future microbiology DOI: 10.2217/fmb-2020-0074 sha: 863a90f34da577a91b15a3e02c1a12c2b007b03a doc_id: 877086 cord_uid: q7e5fbv3 nan • The E protein of SARS-CoV (genetically related to SARS-CoV-2) consists of 76-109 amino acids, ranging in size from 8.4 to 12 kDa. Its primary and secondary structures have a short, hydrophilic amine terminus group of 7-12 amino acids followed by a hydrophobic 25 amino acid transmembrane domain which ends in a hydrophilic carboxyl group terminus [8] . The SARS-CoV-2 E protein includes a triple cysteine motif (NH 2 -. . . L-Cys-A-Y-Cys-Cys-N . . . -COOH) after the transmembrane domain which interacts with a similar motif from S protein terminal C-(NH 2 -. . . S-Cys-G-S-Cys-Cys-K . . . -COOH) [8] . Both motifs interact through disulfide bonds [8] , and NAC may cleave them. This would decrease SARS-CoV-2 infectivity. • In vitro studies have shown NAC to decrease angiotensin II bonds to angiotensin II type 1 receptor in a dosedependent manner [9] . In the COVID-19 context, NAC could block excessive production of angiotensin II, which cannot be cleaved to angiotensin 1-7 by ACE2. This may decrease pulmonary disease severity. • In vitro and clinical studies have shown NAC to block ACE. In one experiment isosorbide dinitrate (vasodilator activity) was administered to six male participants for 48 h, but at 24 h NAC was added (2 g intravenously [iv.] followed by 5 mg/kg/h). Angiotensin II plasma concentrations increased during the first 24 h of isosorbide dinitrate administration but just 2 h after NAC initiation they had decreased from 28 ± 4 to 14 ± 2 ng/l (p < 0.05) [10] . This suggests that, by blocking ACE, NAC may provide protection from the deleterious effects of angiotensin II, a potentially useful activity in a SARS-CoV-2 infection scenario. • The oxidative stress environment created by cytokine storm syndrome and production of reactive oxygen species (ROS) may be attenuated by NAC's antioxidant effect [11] . Also, the SARS-CoV-2 immunopathology may be similar to that of SARS-CoV, which generates an immune response involving diverse pro-inflammatory cytokines (IL-1, IL-2, IL-4, TNF and IFNs). The IFNs are classified in type-I (IFN-α and β), -II (IFN-γ) and -III. Type-I IFNs are suppressed during SARS-CoV infection due to impairment of signal transducer and activator of transcription 1, which ultimately antagonizes IFN. This complex mechanism may also generate delayed IFN response due to cytokine storm syndrome during SARS-CoV-2 infection, possibly explaining COVID-19 pathology. NAC may amplify the signaling functions of toll-like receptor 7 and mitochondrial antiviral signaling protein in restoring type-I IFN production during SARS-CoV-2 infection [11] . • NAC has been shown to restore platelet GSH reserves (in a murine model) which in turn can prevent protein glycosylation by methylglyoxal, a pathologic mechanism in diabetic patients [12] . The SARS-CoV-2 S glycoprotein differs from that of SARS-CoV in that it gains new glycosylation sites (NGTK, NFTI, NLTT and NTSN), allowing SARS-CoV-2 to enter the host cell [5] . Administration of NAC could prevent additional glycosylation events in SARS-CoV-2, thus inhibiting its infectivity and any associated pathologies. • In a recent study the NF-κB was described as a mediator of SARS-CoV-2 pulmonary pathology since it triggers the production of numerous pro-inflammatory cytokines. This process generates macrophage and neutrophil infiltration, both of which cause irreparable damage to pulmonary epithelium cells. NAC was shown to inhibit NF-κB activation in an in vitro influenza (A and B) model [13] ; the proposed mechanism is restauration of thiol pools which may allow ROS scavenging. This is relevant because recent clinical experience has shown that severity of COVID-19 clinical manifestations might be associated with decreased GSH levels and the consequent increased ROS production. Severe COVID-19 cases would therefore probably manifest lower GSH levels, higher ROS levels and greater redox status (ROS/GSH ratio) than milder cases [14] . • In the context of influenza virus infection, NAC administration (100 mg/kg continuous iv. infusion daily for 3 days) was reported to promote clinical improvement in a woman with H1N1 influenza pneumonia; oseltamivir was also employed during treatment [15] . However, other studies have found no beneficial in vitro or vivo effects with NAC administration [16] . NAC (600 mg twice daily) has also been reported to attenuate influenza symptoms in patients ≥65-years old with chronic-degenerative diseases [17] . Given this pandemic's immense health risk, several drugs have been employed with and without clinical evidence for the treatment of COVID-19, NAC among them [18] . Administration of NAC (oral, iv. or inhaled) as an adjuvant treatment in patients with mild-severe COVID-19 symptoms is worth considering as a cost-effective clinical strategy. Currently, there are some clinical trials assessing the potential use of NAC against COVID-19; for example, the 'Efficacy and Safety of Nebulized Heparin-N-acetylcysteine in COVID-19 Patients by Evaluation of Pulmonary Function Improvement (HOPE)' clinical trial is aimed at determining the efficacy of nebulized NAC and heparin in ventilated COVID-19 patients [19] transferred from critical care unit due to clinical improvement; and the number of patients discharged due to clinical improvement. Patients are receiving NAC iv. 6 g/day in addition to other treatments prescribed for COVID-19 [20] . Oral administration of NAC (600 mg/day) could function as a preventive measure, particularly in those repeatedly exposed to possible SARS-CoV-2 carriers (e.g., health workers). This application could be a particularly urgent approach since, despite the use of personal protective equipment, healthcare workers in the USA, Italy, China, Mexico, etc., have become infected while caring for hospitalized patient. Other workers who, due to their job requirements, cannot work at home and/or ensure self-isolation might also benefit from preventive use of NAC administration. If deemed effective, this latter use could potentially help to flatten the exponential contagion curve in several countries. More clinical trials would clearly be needed to validate this application. Basic laboratory and clinical studies are required to confirm possible use of NAC as an element in combating the disease caused by SARS-CoV-2. This would need to be one of myriad efforts to identify additional treatments (novel or not) aimed at halting the current COVID-19 pandemic, or at the very least slowing person-to-person contagion. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 World Health Organization. Coronavirus disease (COVID-19) situation dashboard Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV) A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells N-acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why Coronavirus envelope protein: current knowledge N-acetylcysteine decreases angiotensin II receptor binding in vascular smooth muscle cells N-acetylcysteine inhibits angiotensin converting enzyme in vivo Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus N-acetylcysteine attenuates systemic platelet activation and cerebral vessel thrombosis in diabetes N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV) Endogenous deficiency of glutathione as the most likely cause of serious manifestations and death in COVID-19 patients High-dose N-acetylcysteine therapy for novel H1N1 influenza pneumonia N-acetylcysteine lacks universal inhibitory activity against influenza A viruses Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment Treatments administered to the first 9152 reported cases of COVID-19: a systematic review COVID-19 treatment HOPE protocol A study of N-acetylcysteine in patients with COVID-19 infection Both authors equally contributed with the manuscript. We thank J Lindsay-Edwards, an English copy editor, for checking manuscript grammar and style. M-P Rosa-Ester thanks Fundación IMSS A.C. for use of the Centro de Investigación en Salud JK Rodríguez. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.